Connection
Eric Wu to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Eric Wu has written about Carcinoma, Non-Small-Cell Lung.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.164 |
|
|
|
-
Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiol. 2015 Jun; 39(3):307-12.
Score: 0.058
-
Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. Lung Cancer. 2014 Dec; 86(3):350-7.
Score: 0.056
-
Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2013; 16(2):260-2.
Score: 0.050